Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9253214 | 0.85 | CYP3A4 (0.48) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL6338910 | 0.82 | CD44 (0.48) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL1772150 | 0.82 | CD44 (0.48) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL8387574 | 0.82 | GABRA1 (0.48) | CD44CYP3A4TDP1TSHRGABRA1 | |
| SCHEMBL2687017 | 0.82 | GABRA1 (0.48) | CD44CYP3A4TDP1TSHRGABRA1 | |
| SCHEMBL10338299 | 0.79 | CD44 (0.50) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL2056782 | 0.76 | CA2 (0.46) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL8601659 | 0.76 | CD44 (0.42) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL931847 | 0.74 | TSHR (0.48) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL279180 | 0.74 | CYP3A4 (0.39) | CD44CYP3A4TDP1TSHRPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| EP-3636636-B1 | PYRIDONE COMPOUND AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE | MITSUI CHEMICALS AGRO INC (JP) | 2022-07-06 | — | — | EP | disclosed |
| US-11066434-B2 | Metal complexes comprising aniline type ligands | UMICORE AG & CO. KG | 2021-07-20 | — | — | US | disclosed |
| US-20200239504-A1 | METAL COMPLEXES COMPRISING ANILINE TYPE LIGANDS | UMICORE AG & CO. KG (DE) | 2020-07-30 | — | — | US | disclosed |
| CN-110139889-A | COMPOSITIONS AND ARTICLES MADE FROM BRANCHED POLYETHERIMIDES | 沙特基础工业全球技术有限公司 | 2019-08-16 | — | — | CN | disclosed |
| CN-110121519-A | Polyimide oligomers, composition, manufacturing method and application thereof | 沙特基础工业全球技术有限公司 | 2019-08-13 | — | — | CN | disclosed |
| CN-110121496-A | The synthesis of reactive intermediate and application thereof for polyetherimide | 沙特基础工业全球技术有限公司 | 2019-08-13 | — | — | CN | disclosed |
| CN-110088169-A | Method for preparing polyetherimide | 沙特基础工业全球技术有限公司 | 2019-08-02 | — | — | CN | disclosed |
| CN-110050014-A | Method of making polyetherimides and polyetherimides produced therefrom | 沙特基础工业全球技术有限公司 | 2019-07-23 | — | — | CN | disclosed |
| CN-109952338-A | Poly- (acid imide) oligomer of telechelic, its Manufacturing approach and use | 沙特基础工业全球技术有限公司 | 2019-06-28 | — | — | CN | disclosed |
| CN-109890876-A | Method for producing polymer particles and polymer particles produced thereby | 沙特基础工业全球技术有限公司 | 2019-06-14 | — | — | CN | disclosed |
| CN-109563267-A | For manufacturing method, thus poly- (acid imide) prepolymer powder for preparing and the varnish of poly- (acid imide) prepolymer powder and varnish and poly- (acid imide) prepared therefrom | 沙特基础工业全球技术有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-106133056-B | Flame-retardant polyester composition and product | 沙特基础工业全球技术有限公司 | 2019-04-02 | — | — | CN | disclosed |
| US-20180002335-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2018-01-04 | — | — | US | disclosed |
| US-9676676-B2 | Selective olefin metathesis with cyclometalated ruthenium complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-06-13 | — | — | US | disclosed |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CD44 2378/4885CYP3A4 2433/4885TDP1 1532/4885 |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CD44 2756/4885CYP3A4 2340/4885TDP1 1361/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | CD44 712/4885CYP3A4 3742/4885TDP1 705/4885 |
| US-20180002335-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | CD44 1311/4885CYP3A4 2491/4885TDP1 1090/4885 |
| US-20200239504-A1 | METAL COMPLEXES COMPRISING ANILINE TYPE LIGANDS | SQLE, SOAT1, SOAT2 | CD44 3823/4885CYP3A4 31/4885TDP1 3885/4885 |
| US-11066434-B2 | Metal complexes comprising aniline type ligands | SQLE, SOAT1, SOAT2 | CD44 3823/4885CYP3A4 31/4885TDP1 3885/4885 |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | CD44 4332/4885CYP3A4 853/4885TDP1 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.